Attached files
| file | filename |
|---|---|
| 10-K - 10-K - ALNYLAM PHARMACEUTICALS, INC. | alny-20191231.htm |
| EX-32.2 - EX-32.2 - ALNYLAM PHARMACEUTICALS, INC. | exhibit-322.htm |
| EX-32.1 - EX-32.1 - ALNYLAM PHARMACEUTICALS, INC. | exhibit-321.htm |
| EX-31.2 - EX-31.2 - ALNYLAM PHARMACEUTICALS, INC. | exhibit-312.htm |
| EX-31.1 - EX-31.1 - ALNYLAM PHARMACEUTICALS, INC. | exhibit-311.htm |
| EX-21.1 - EX-21.1 - ALNYLAM PHARMACEUTICALS, INC. | exhibit-211.htm |
| EX-10.50 - EX-10.50 - ALNYLAM PHARMACEUTICALS, INC. | exhibit-1050.htm |
| EX-10.10 - EX-10.10 - ALNYLAM PHARMACEUTICALS, INC. | exhibit-1010.htm |
| EX-4.2 - EX-4.2 - ALNYLAM PHARMACEUTICALS, INC. | exhibit-42.htm |
| EX-3.2 - EX-3.2 - ALNYLAM PHARMACEUTICALS, INC. | exhibit-32.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statement on Forms S-8 (Nos. 333-190498, 333-127450, 333-116151, 333-148114, 333-157633, 333-165105, 333-172370, 333-207251, 333-219840 and 333-226533) and Form S-3 (No. 333-217688) of Alnylam Pharmaceuticals, Inc. of our report dated February 13, 2020 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/PricewaterhouseCoopers LLP
Boston, Massachusetts
February 13, 2020